Overview
Portfolio
More
HighLight Capital (弘晖基金)
Tokyo, Japan
HighLight Capital focuses on strategic emerging sectors that drive China’s modernisation, leveraging deep expertise in chemistry, biology, materials and engineering. It invests in health‑tech and biotech companies—includ...
Portfolio
28+
Employees
30+
Founded
2014
AUM
≈ $550.0M
Investment focus
Stages
Seed → Series A
Industries
HardwareArtificial IntelligenceBiotechnologyHealthcare Technology
Geographic scope
China
Fund details
Funds
HLC USD Fund IV
Vintage 2023 • $550.0M
Sources
HighLight Capital (弘晖基金)
HighLight Capital focuses on strategic emerging sectors that drive China’s modernisation, leveraging deep expertise in chemistry, biology, materials and engineering. It invests in health‑tech and biotech companies—including drug development, precision instruments and medical devices—as well as technology manufacturing firms in semiconductors, advanced manufacturing, new materials, AI and robotics. The firm combines independent research with ecosystem enablement to back high‑value, long‑term growth opportunities.
Portfolio
28+
Employees
30+
Founded
2014
AUM
≈ $550.0M
Funds
HLC USD Fund IV · Vintage 2023 • $550.0M
Stages
Seed → Series A
Industries
HardwareArtificial IntelligenceBiotechnologyHealthcare TechnologyIndustrial Automation
Geographic scope
China
Sources
Showing 13 of 13 matched portfolio companies
G Healthy provides an integrated automation platform for hospital pharmacies, intravenous admixture services, and medical consumable management. Its solution combines robotics, IoT sensors, RFID, and cloud‑based software to automate drug storage, dispensing, packaging, and logistics, delivering real‑time traceability, dose accuracy, and space optimization for large Chinese hospitals.
Hongyixin designs and develops automotive electronic chips for various vehicle systems. Their products enable automakers to enhance vehicle performance, safety, and efficiency through advanced semiconductor solutions.
Inmagene is developing differentiated therapies for immunological and inflammatory diseases using its proprietary QuadraTek® platform, which optimizes safety and efficacy. The company targets conditions such as atopic dermatitis and alopecia areata by inhibiting the OX40/OX40L signaling pathway to improve patient outcomes.
Funding: $216.0M
Rough estimate of the amount of funding raised
Funding: $216.0M
Rough estimate of the amount of funding raised
Junyi Auto delivers integrated industrial automation platforms that link machinery, sensors, and control systems into a single, data‑driven solution. Their modular hardware, centralized big‑data analytics, and real‑time dashboards enable manufacturers to monitor performance, optimize processes, and predict maintenance, reducing downtime and improving productivity across diverse production lines.
The company supplies full‑stack positioning solutions for Physical AI, integrating automotive‑grade GNSS chips, IMU modules, and multi‑source sensor‑fusion algorithms. Its hardware and software provide reliable, secure, high‑precision attitude and absolute positioning for autonomous driving and other demanding applications.
Merck is a research‑intensive biopharmaceutical company that discovers, develops, and manufactures prescription medicines and vaccines across oncology, infectious disease, cardiovascular, immunology, neuroscience, and ophthalmology. It leverages AI‑driven target identification, translational medicine platforms, and a global clinical‑trial network to accelerate development, while its GMP manufacturing capacity and patient‑access programs support large‑scale distribution and affordability.
Funding: $586.0K
Rough estimate of the amount of funding raised
Funding: $586.0K
Rough estimate of the amount of funding raised
Rgenta Therapeutics develops oral, small-molecule RNA-targeting medicines aimed at treating previously incurable oncology and neurological disorders. By focusing on RNA regulation, the company addresses the challenge of drugging targets that have been difficult to reach with traditional therapies.
Funding: $8.0M
Rough estimate of the amount of funding raised
Funding: $8.0M
Rough estimate of the amount of funding raised
TopOlefin Technology specializes in the development and production of high-performance polymer materials, including SOOC and TOPC, utilizing proprietary polymerization techniques to achieve superior optical properties and thermal stability. The company addresses the need for advanced materials in precision optics, medical packaging, and automotive components, filling domestic technology gaps and reducing reliance on international suppliers.
Founded 2020
United Imaging builds ultra‑high‑field MRI, high‑definition PET/MR, and total‑body PET‑CT systems that deliver whole‑body imaging with superior resolution, faster scans, and low radiation dose. Their integrated hardware and AI‑assisted software enable clinicians to capture anatomical, functional, and molecular data in a single exam, supporting earlier diagnosis and precise treatment planning for large hospitals and research centers.
Ymtc provides a cloud‑based data platform that unifies data ingestion, scalable processing, and interactive visualizations in a single environment. The solution automates pipeline creation from batch and streaming sources, offers auto‑scaling distributed compute, and includes role‑based security, governance, and integration APIs to connect with existing enterprise systems, enabling faster, self‑service analytics for mid‑size to large organizations.
Yuwell Medical supplies certified medical devices—including patient monitors, ECG machines, infusion pumps, and respiratory support equipment—for hospitals, clinics, and home‑care providers. Its products feature built‑in connectivity to hospital information systems via HL7/DICOM, user‑friendly touchscreen interfaces, and secure cloud‑based remote diagnostics. Yuwell also offers integrated software for real‑time vital sign aggregation and comprehensive after‑sales support, including installation, training, and maintenance.
Zentalis is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target key biological pathways in cancer, specifically utilizing WEE1 inhibition to treat various malignancies. Their therapies aim to improve outcomes for patients with platinum-resistant ovarian cancer and other solid tumors, addressing the need for effective treatment options in challenging cancer types.
100+
10K+Approximate amount of employees
Funding: $235.5M
Rough estimate of the amount of funding raised
Funding: $235.5M
Rough estimate of the amount of funding raised
Zylox develops interventional and implantable devices specifically designed for peripheral vascular applications, utilizing targeted solutions to enhance blood flow in patients with vascular diseases. Their technology directly addresses vascular occlusions, improving patient outcomes and minimizing the need for invasive surgical procedures.
Showing 12 of 15 unmatched portfolio companies